Chemistree Technology Inc. (CSE: CHM) (OTC: CHMJF) this morning announced its entry into a funding agreement with The Physician’s Choice CBD LLC (“PCCBD”) of Phoenix, Arizona, which is dedicated to researching, developing and utilizing the highest quality of hemp-derived cannabidiol (“CBD”) in combination with well-studied and effective supplements to assist in supporting and regulating various symptoms.
“This investment in The Physician’s Choice CBD is a great opportunity for Chemistree,” Chemistree President Karl Kottmeier commented in the news release. “Dr. Grove and Dr. Kubitz are board certified practicing physicians with training at Harvard and the Mayo Clinic, specializing in pain management. Their collective education and practical experience is industry-leading and their commitment to the health of their patients and to developing real solutions to pain management with cannabidiol-based supplements is truly inspiring. The investment we are making into PCCBD gives us exposure to an entirely new industry and we are excited to assist wherever we can to see PCCBD continue to grow its sales and product offerings into a multi-state success. I encourage everyone to visit www.pccbd.com to learn more about this great new company and their comprehensive and growing line of CBD supplements.”
To view the full press release, visit http://cnw.fm/M9ciC
About Chemistree Technology Inc.
Chemistree Technology Inc. is an investment company dedicated to the U.S. cannabis sector, endeavoring to provide turn-key solutions for the regulated cannabis industry. The Company’s corporate strategy is to acquire and develop vertically integrated cannabis assets, leveraging management’s decades of expertise in the cannabis industry and corporate finance to own and operate licensed cultivation, processing, distribution and retail facilities. The Company currently owns assets in Washington State used to operate the Sugarleaf brand, prospective cannabis cultivation lands in California, a 50% interest in a Humboldt County, California cannabis processing company, has completed its first investment in the Canadian cannabis sector through its investment in Pasha Brands and has a pipeline of assets to grow its base of business. For more information, visit www.Chemistree.ca
NOTE TO INVESTORS: The latest news and updates relating to CHMJF are available in the company’s newsroom at http://cnw.fm/CHMJF
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000
For more information please visit https://www.CannabisNewsWire.com
Do you have a questions or are you interested in working with CNW? Ask our Editor
READ MORE: https://www.cannabisnewswire.com/cannabisnewsbreaks/cannabisnewsbreaks-chemistree-technology-inc-cse-chm-otc-chmjf-enters-agreement-to-acquire-ownership-stake-in-the-physicians-choice-cbd-llc/